InnoCare Pharma's Phase III Trial of Fadeucravacitinib Meets Primary Endpoint
MT Newswires Live
Jul 28
InnoCare Pharma (HKG:9969, SHA:688428) said the Phase III clinical trial of fadeucravacitinib met its primary endpoint, according to a Hong Kong bourse disclosure on Monday.
The pharmaceutical company's Hong Kong shares rose 1% during Tuesday's midday trade.
The drug was tested as a treatment for patients with moderate-to-severe plaque psoriasis.
The drug's safety profile was consistent with previous clinical studies and no new safety signals were identified. Results from the study will be presented at upcoming international scientific congresses and in medical journals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.